Drug intelligence / Profile preview

FP0011

Development stage: Unknown
Lead developer: Domain Therapeutics
Modality: Small Molecules

Overview

FP0011 is a small molecule antiglutamatergic compound developed for its symptomatic and disease-modifying effects in neurological disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. It acts as an antagonist of metabotropic glutamate receptors (mGluRs), modulating presynaptic glutamate release and providing neuroprotective properties. The drug has been investigated primarily for its potential to treat ALS and Parkinson's disease by reducing excitotoxicity mediated by excessive glutamate signaling[1][2][4].

Targets

mGluR (Metabotropic glutamate receptors)

Beyond the preview

Go deeper on FP0011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FP0011.

Explore the full profile